TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06724016: Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors

Sponsor: Hanmi Pharmaceutical Company Limited · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 292 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT06724016 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06724016 Rescue Dossier →